JR-171

JCR Pharmaceuticals Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	JR-171
Also known as	lepunafusp alfa
Sponsor	JCR Pharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I) (PHASE1, PHASE2)
A Study of JR-171 in Patients With Mucopolysaccharidosis I (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JR-171 CI brief — competitive landscape report
JR-171 updates RSS · CI watch RSS
JCR Pharmaceuticals Co., Ltd. portfolio CI